SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001047469-20-003566
Filing Date
2020-06-12
Accepted
2020-06-12 16:24:33
Documents
5
Period of Report
2020-07-29

Document Format Files

Seq Description Document Type Size
1 PRE 14A a2241853zpre14a.htm PRE 14A 989117
2 G787085.JPG g787085.jpg GRAPHIC 16843
3 G761950.JPG g761950.jpg GRAPHIC 7584
4 G223772BGI001.JPG g223772bgi001.jpg GRAPHIC 321270
5 G223772BGI002.JPG g223772bgi002.jpg GRAPHIC 232767
  Complete submission text file 0001047469-20-003566.txt   1787415
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37558 | Film No.: 20960490
SIC: 2834 Pharmaceutical Preparations